Cargando…

Association of Benzodiazepine Receptor Agonist Use With Changes in Psoriasis Severity in Adult Population: A Population-Based Study

To date, it remains uncertain whether benzodiazepine receptor agonists (BZRAs) are aggravating factors even though these drugs can elevate the levels of biomarkers associated with the development of psoriasis. Therefore, this study aimed to investigate the association of BZRA use with changes in pso...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Ke-Ting, Li, I-Hsun, Kao, Hui-Han, Chen, Yi-Hsien, Zhong, Pei-Xun, Kao, Li-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287000/
https://www.ncbi.nlm.nih.gov/pubmed/34290604
http://dx.doi.org/10.3389/fphar.2021.596375
_version_ 1783723827539214336
author Pan, Ke-Ting
Li, I-Hsun
Kao, Hui-Han
Chen, Yi-Hsien
Zhong, Pei-Xun
Kao, Li-Ting
author_facet Pan, Ke-Ting
Li, I-Hsun
Kao, Hui-Han
Chen, Yi-Hsien
Zhong, Pei-Xun
Kao, Li-Ting
author_sort Pan, Ke-Ting
collection PubMed
description To date, it remains uncertain whether benzodiazepine receptor agonists (BZRAs) are aggravating factors even though these drugs can elevate the levels of biomarkers associated with the development of psoriasis. Therefore, this study aimed to investigate the association of BZRA use with changes in psoriasis severity. All data were sourced from the National Health Insurance system in Taiwan. We conducted a population-based retrospective cross-sectional study of 15,727 psoriasis patients who received BZRAs (BZRA users), and 18,856 psoriasis patients who did not receive BZRAs (nonusers). At least a 1-year washout period without any BZRA prescriptions was required. The main outcome was the change in psoriasis severity between before and after BZRA exposure. This study detected the exacerbation of psoriasis severity in mild psoriasis population by using a logistic model. Then, this study carried another logistic model among those patients who had severe psoriasis to calculate the odds ratios (ORs) for the improvement of the psoriasis severity. Among patients with mild psoriasis, BZRA users had a significantly higher probability of psoriasis severity exacerbation (IPTW-adjusted OR = 1.46). Mild psoriasis patients who received high and low doses of BZRAs had 1.70- and 1.39-fold higher probabilities of psoriasis severity exacerbation, respectively, than the non-users. Furthermore, in the severe psoriasis population, more low-dose BZRA users improved psoriasis severity than non-users. In conclusion, this study provided clinical evidence of the effects of BZRA use on patients with psoriasis severity. Among patients with mild psoriasis, high-dose BZRA users may be associated with the changes in psoriasis severity. However, low-dose BZRA exposure only slightly exacerbated disease severity among patients with mild psoriasis. Accordingly, clinicians should evaluate the risks and benefits of the BZRA usage.
format Online
Article
Text
id pubmed-8287000
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82870002021-07-20 Association of Benzodiazepine Receptor Agonist Use With Changes in Psoriasis Severity in Adult Population: A Population-Based Study Pan, Ke-Ting Li, I-Hsun Kao, Hui-Han Chen, Yi-Hsien Zhong, Pei-Xun Kao, Li-Ting Front Pharmacol Pharmacology To date, it remains uncertain whether benzodiazepine receptor agonists (BZRAs) are aggravating factors even though these drugs can elevate the levels of biomarkers associated with the development of psoriasis. Therefore, this study aimed to investigate the association of BZRA use with changes in psoriasis severity. All data were sourced from the National Health Insurance system in Taiwan. We conducted a population-based retrospective cross-sectional study of 15,727 psoriasis patients who received BZRAs (BZRA users), and 18,856 psoriasis patients who did not receive BZRAs (nonusers). At least a 1-year washout period without any BZRA prescriptions was required. The main outcome was the change in psoriasis severity between before and after BZRA exposure. This study detected the exacerbation of psoriasis severity in mild psoriasis population by using a logistic model. Then, this study carried another logistic model among those patients who had severe psoriasis to calculate the odds ratios (ORs) for the improvement of the psoriasis severity. Among patients with mild psoriasis, BZRA users had a significantly higher probability of psoriasis severity exacerbation (IPTW-adjusted OR = 1.46). Mild psoriasis patients who received high and low doses of BZRAs had 1.70- and 1.39-fold higher probabilities of psoriasis severity exacerbation, respectively, than the non-users. Furthermore, in the severe psoriasis population, more low-dose BZRA users improved psoriasis severity than non-users. In conclusion, this study provided clinical evidence of the effects of BZRA use on patients with psoriasis severity. Among patients with mild psoriasis, high-dose BZRA users may be associated with the changes in psoriasis severity. However, low-dose BZRA exposure only slightly exacerbated disease severity among patients with mild psoriasis. Accordingly, clinicians should evaluate the risks and benefits of the BZRA usage. Frontiers Media S.A. 2021-07-05 /pmc/articles/PMC8287000/ /pubmed/34290604 http://dx.doi.org/10.3389/fphar.2021.596375 Text en Copyright © 2021 Pan, Li, Kao, Chen, Zhong and Kao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Pan, Ke-Ting
Li, I-Hsun
Kao, Hui-Han
Chen, Yi-Hsien
Zhong, Pei-Xun
Kao, Li-Ting
Association of Benzodiazepine Receptor Agonist Use With Changes in Psoriasis Severity in Adult Population: A Population-Based Study
title Association of Benzodiazepine Receptor Agonist Use With Changes in Psoriasis Severity in Adult Population: A Population-Based Study
title_full Association of Benzodiazepine Receptor Agonist Use With Changes in Psoriasis Severity in Adult Population: A Population-Based Study
title_fullStr Association of Benzodiazepine Receptor Agonist Use With Changes in Psoriasis Severity in Adult Population: A Population-Based Study
title_full_unstemmed Association of Benzodiazepine Receptor Agonist Use With Changes in Psoriasis Severity in Adult Population: A Population-Based Study
title_short Association of Benzodiazepine Receptor Agonist Use With Changes in Psoriasis Severity in Adult Population: A Population-Based Study
title_sort association of benzodiazepine receptor agonist use with changes in psoriasis severity in adult population: a population-based study
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287000/
https://www.ncbi.nlm.nih.gov/pubmed/34290604
http://dx.doi.org/10.3389/fphar.2021.596375
work_keys_str_mv AT panketing associationofbenzodiazepinereceptoragonistusewithchangesinpsoriasisseverityinadultpopulationapopulationbasedstudy
AT liihsun associationofbenzodiazepinereceptoragonistusewithchangesinpsoriasisseverityinadultpopulationapopulationbasedstudy
AT kaohuihan associationofbenzodiazepinereceptoragonistusewithchangesinpsoriasisseverityinadultpopulationapopulationbasedstudy
AT chenyihsien associationofbenzodiazepinereceptoragonistusewithchangesinpsoriasisseverityinadultpopulationapopulationbasedstudy
AT zhongpeixun associationofbenzodiazepinereceptoragonistusewithchangesinpsoriasisseverityinadultpopulationapopulationbasedstudy
AT kaoliting associationofbenzodiazepinereceptoragonistusewithchangesinpsoriasisseverityinadultpopulationapopulationbasedstudy